You are here

Companies & Spin-Offs

IDEA Bio-Medical has developed a high definition, ultra-fast biological cell-imaging system WiScanTM capable of high resolution imaging at high speeds. IDEA Bio-Medical was established in 2007 by IDEA Machine Development, Design and Production Ltd. High content screening - developed by professors Benjamin Geiger and Zvi Kam during their research at the Weizmann Institute of Science. Know-how, expertise and...Read more >
HY BIOPHARMA INC. is a dermatology specialty company focused on the development of its innovative photodynamic therapy using topically-applied synthetic hypericin with safe visible light, to treat early-stage Cutaneous T Cell Lymphoma (CTCL) and psoriasis. The drug, HBP-347, is a culmination of 15 years of research and development carried out by Prof. Mazur and Lavie at New York University and the Weizmann Institute...Read more >
NewCO2Fuels Ltd., founded in 2011, commercializes a technology conceived by Prof. Jacob Karni’s laboratory at the Weizmann Institute of Science. Prof. Karni and his team conducted eight years of research on high-temperature CO2 dissociation and showed that the technology has the ability to convert CO2 into fuels. NewCO2Fuels is managed by experienced executives in the high technology and cleantech industries and...Read more >
Catalyst AgTech Ltd. is developing a breakthrough technology, which minimalizes the environmental impact of agrochemical products, a major issue in modern agrotechnology. Catalyst AgTech's technology solves the conflict between the growing demand for more essential pesticides and the need to prevent any negative impact on the environment. The solution leads to billions of dollars in more business while alleviating...Read more >
LifeMap offers integrated, streamlined solutions that empower life scientists worldwide to conduct cutting edge basic, clinical and applied biomedical research. LifeMap’s products are used in more than 3,000 institutions including academia, research hospitals, patent offices, and leading biopharma and diagnostic companies. Operations worldwide are carried out from our offices in California, Massachusetts, New Jersey...Read more >
PROLOR Biotech is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology and Reversible Pegylation technology, primarily to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins and the Reversible...Read more >
NDS Group Ltd. was established in 1985 and developed smart cards to prevent unauthorized access to computer data and satellite television broadcasts. The technology is based on an algorithm developed at the Weizmann Institute's Faculty of Mathematics and Computer Sciences. NDS was traded on Nasdaq (NNDS) and later (2012) acquired by Cisco for approximately $5 billion.Read more >
Kadimastem Ltd. is developing innovative stem cell based therapeutics invented by Prof. Michel Revel at the Weizmann Institute. Prof. Revel currently serves as the Company's Chief Scientist. Kadimastem holds an exclusive license from Yeda Research and Development Co. Ltd. (the Technology Transfer Company of the Weizmann Institute of Science) regarding the commercialization of embryonic stem cells for the treatment...Read more >
InterPharm Laboratories Ltd., founded in 1978 and today it is a subsidiary of Merck-Serono. For many years InterPharm was the largest biotechnology company in Israel, developing recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases. All the products developed at InterPharm Laboratories (Interferon b, Interleukin-6 and soluble TNF receptors) emanated from research performed at...Read more >
Deep Transcranial Magnetic Stimulation (TMS) is a novel patented technology, enabling non-invasive direct stimulation of deep neuronal pathways, with almost no side effects. This ability may be useful for basic research and a broad range of psychiatric and neurological applications. Brainsway was founded in March 2003, and has exclusive rights on the Deep TMS technology developed by Dr. Abraham Zangen from the...Read more >
BiondVax Pharmaceuticals Ltd. is developing innovative peptide based vaccines conceptualized and invented by Prof. Ruth Arnon at the Weizmann Institute, Israel. The first application is a universal multi-season/multi-strain influenza vaccine that provides long-term protection against a vast majority of flu viruses. Current influenza vaccines are strain dependent and do not confer protection against emerging strains...Read more >

Pages